Headquarters: San Francisco, California, USA
Founded: February 2016
Founder(s): Hugo Peris, Justin Hanes
Notable Investors: Camden Partners
Spiral Therapeutics is a biotechnology company that focuses on the development of therapeutics for the treatment of hearing loss and related conditions. The company is based in Durham, North Carolina, and was founded in 2010.
Spiral Therapeutics’ lead product candidate is a drug delivery platform called the Extended Release Local Anesthetic (ERLA) technology, which is designed to provide sustained release of therapeutic agents in the inner ear. This technology is intended to treat hearing loss associated with various conditions, including otitis media, noise-induced hearing loss, and age-related hearing loss.
In addition to the ERLA technology, Spiral Therapeutics is also developing other drug delivery platforms for the treatment of inner ear disorders. The company has partnerships with academic institutions and research organizations to support the development of its product pipeline.
Spiral Therapeutics has received funding from several sources, including the National Institutes of Health (NIH) and private investors.
40 million people in the US qualify for hearing loss treatment, but there are no drugs approved for hearing loss. Drug delivery to the inner ear remains the hardest challenge.
Precise, non-invasive placement techniques, combined with long-acting delivery systems have the potential to overcome the barriers of drug delivery to the inner ear.
Inflammation and neurodegeneration are the origin of 90% of inner ear disorders. Biomarkers of active disease and improved patient selection are necessary to overcome the challenges of clinical development.
Inspired by ophthalmology, Spiral’s platform addresses hearing loss by delivering the right drugs, to the right place, for the right duration.